Skip to content
MARKETS / NASDAQ / TAOX
NASDAQ · FINANCE SERVICES · SMALL CAP

TAO Synergies Inc. TAOX

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$299,061
$-28.7M
In brief

What this company does

We are principally focused on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. We are also evaluating Bryostatin-1 for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome and Multiple Sclerosis, which have undergone pre-clinical testing. On June 9, 2025, in connection with our previously announced exploration of strategic opportunities, we announced the launch of a differentiated cryptocurrency treasury strategy focused on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI.

Written from the business description in TAO Synergies Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 299,061.00
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.3 · Net income -28.7
-10M-20M2019202020212022202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−9609 cents
lost on every revenue dollar
ROE
FY2025 · ROE -213.5%
-100%-200%2019202020212022202320242025

Each USD of equity lost 214 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -5.2
-4M-8M2019202020212022202320242025

Total assetsUSD 25.8M
EquityUSD 21.1M
CashUSD 5.5M
Current ratio13.99×

Equity funds 81% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.00.0·····
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0·
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0·
Income tax $B0.00.00.0····
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B··−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−8.81−10.9929.56−0.81−2.5112.033.01
Dividend / sh $·······
Payout %·······
ROE %−213.5−84.5−21.2−16.8−65.2−112.6−86.9
Shares out B0.010.000.000.010.010.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 2 failures in 28 reconciliationsAUDITED

Reconciled in 5 of 19 fiscal years. 65 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityFinance Services
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image